STAAR Surgical Announces Approval By Health Canada of Its EVO Visian ICL for Surgeons and Their Patients in Canada MONROVIA, CA

STAAR Surgical Announces Approval

By Health Canada of Its EVO Visian ICL for Surgeons and Their Patients in Canada

MONROVIA, CA, May 13, 2016---STAAR

Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems

for the eye, was notified yesterday of the approval of its EVO Visian ICL, STAAR's Implantable Collamer Lens,

for distribution in Canada by the Medical Devices Bureau of Health Canada.

With extensive clinical experience

globally, the EVO ICL is STAAR's next-generation lens implanted in the eye that works with the patient's natural eye

to correct vision. Unlike traditional contact lenses that are placed on the surface of the eye, the EVO ICL is positioned inside

the eye between the iris and the natural lens where it stays indefinitely.

"We are very pleased with Health Canada's approval

that allows us to offer the EVO ICL for myopia, with a broad power range of -3.0 to -18.0 diopters, to our surgeons and their patients

in Canada. This represents an important new treatment option for eligible patients between 21 and 45 years old living with nearsightedness.

This approval reinforces our deep commitment to patients seeking visual freedom, as we continue to build our growing EVO ICL portfolio.

STAAR looks forward to bringing this visual freedom choice to the Canadian refractive surgery market," said Caren Mason,

The EVO ICL has an extensive clinical history of safety and

effectiveness, as was recently reinforced at the American Society of Cataract and Refractive Surgery (ASCRS) Meeting earlier

this month in New Orleans, Louisiana, as part of the Evolution of Visual Freedom initiative. The EVO ICL, with its central

hole, offers premium refractive outcomes with efficiency and comfort for both the patient and the surgeon by eliminating the extra

surgical step of the peripheral iridotomy. Approximately 200,000 lenses from the EVO ICL product family have been implanted globally

to date. Clinical data show that the EVO ICL provides outstanding, predictable correction of high degrees of refractive errors,

with the vast majority of patients achieving and maintaining 20/20 or better visual acuity through five years of follow up.1

Review of the peer-reviewed published literature demonstrates an excellent safety profile: specifically, eight studies including

data from 1,291 eyes followed for up to five years describe a zero incidence of significant complications.2

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery

for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems.

These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses.

All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in

refractive surgery is called an Implantable Collamer Lens or "ICL". Nearly 600,000 Visian ICLs have been implanted

to date. To learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 360 employees and markets lenses in over

60 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo, CA and Monrovia, CA.

For more information, please visit the Company's website at www.staar.com.

All statements in this press release that are not statements

of historical fact are forward-looking statements, including statements about any of the following: statements regarding products

and their safety or efficacy, or potential future sales in Canada or elsewhere, and any statements of assumptions underlying any

of the foregoing. Important factors that could cause actual results to differ materially from those indicated by such forward-looking

statements are set forth in the Company's Annual Report on Form 10-K for the year ended January 1, 2016, under the caption

"Risk Factors", which is on file with the Securities and Exchange Commission and available in the "Investor Information"

section of the company's website under the heading "SEC Filings."

These statements are based on expectations and assumptions as

of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ

materially from those described in the forward-looking statements.